Skip to content

Candel Therapeutics, Inc.

CADL

CIK 0001841387 · Biological Products, (No Diagnostic Substances) · Nasdaq

← back to feed
Revenue (TTM)
$124K
0.0% YoY Q1 May 2026
Net Income (TTM)
−$17.55M
+30.8% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.31
+58.6% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-39,353.2%
Q1 May 2026
Net Margin
-14,150.8%
Q1 May 2026
Free Cash Flow (TTM)
−$46.73M
Q1 May 2026
Cash
$194.83M
Q1 May 2026
Total Debt
$1.73M
Q1 May 2026
Shares Outstanding
73.27M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings